Immuron (IMRN) EBITDA (2016 - 2024)
Immuron (IMRN) posted quarterly EBITDA of $1660259127.7 billion for Q4 2024, up 82189906661311.72% year-over-year from N/an in Q1 2024, and up 82189906661311.72% quarter-over-quarter from -$2.0 million in Q4 2023.
Immuron (IMRN) EBITDA (2016 - 2024) Analysis & Trends
Immuron's EBITDA history runs 9 years deep, the most recent figure standing at $1660259127.7 billion for Q4 2024.
- In Q4 2024, EBITDA rose 82189906661311.72% year-over-year to $1660259127.7 billion; the TTM figure through Dec 2024 stood at $1660259127.7 billion (up 45788954984146.3% YoY), while the FY2025 annual figure was -$3.5 million, up 8.95% from the prior year.
- EBITDA for Q4 2024 stood at $1660259127.7 billion, up from -$2.0 million in the prior quarter.
- The five-year high for EBITDA was $1660259127.7 billion in Q4 2024, with the low at -$2.0 million in Q4 2023.
- The 5-year median for EBITDA is -$205032.1 (2020), against an average of $276709854.6 billion.
- The sharpest annual moves came in 2022 and 2024: EBITDA tumbled 2546.58% in 2022, then soared 82189906661311.72% in 2024.
- Immuron's EBITDA stood at -$57371.6 in 2020, then surged by 76.77% to -$13326.4 in 2021, then sank by 2546.58% to -$352692.6 in 2022, then sank by 472.74% to -$2.0 million in 2023, then jumped by 82189906661311.72% to $1660259127.7 billion in 2024.
- Business Quant data shows IMRN's EBITDA at $1660259127.7 billion in Q4 2024, -$2.0 million in Q4 2023, and -$1.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,127.73 Bn |
| Dec 31, 2023 | -2.02 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -352,692.59 |
| Dec 31, 2021 | -13,326.36 |
| Dec 31, 2020 | -57,371.61 |
| Dec 31, 2019 | -15,191.40 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.84 Mn |
| Dec 31, 2016 | 2.55 Mn |
| Jun 30, 2016 | 4.33 Mn |